Aclaris Therapeutics Company Insiders
ACRS Stock | USD 2.90 0.01 0.35% |
Aclaris Therapeutics' insiders are aggressively buying. The analysis of insiders' sentiment of trading Aclaris Therapeutics stock suggests that vertually all insiders are extremely bullish at this time. Aclaris Therapeutics employs about 86 people. The company is managed by 17 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 5.06 employees per reported executive.
Aclaris Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-11-19 | Anand Mehra | Acquired 666666 @ 2.25 | View | ||
2024-07-30 | Braden Michael Leonard | Acquired 173730 @ 1.3 | View | ||
2024-07-22 | Braden Michael Leonard | Acquired 17716 @ 1.33 | View | ||
2024-07-18 | Braden Michael Leonard | Acquired 130317 @ 1.3 | View | ||
2024-07-05 | Braden Michael Leonard | Acquired 123017 @ 1.15 | View | ||
2024-07-03 | Braden Michael Leonard | Acquired 143288 @ 1.16 | View | ||
2024-07-01 | Braden Michael Leonard | Acquired 107434 @ 1.14 | View | ||
2024-06-27 | Braden Michael Leonard | Acquired 235000 @ 1.15 | View | ||
2024-06-17 | Braden Michael Leonard | Acquired 150000 @ 1.13 | View | ||
2024-06-13 | Braden Michael Leonard | Acquired 528621 @ 1.15 | View | ||
2024-06-11 | Braden Michael Leonard | Acquired 1000000 @ 1.08 | View |
Monitoring Aclaris Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Aclaris |
Aclaris Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Aclaris Therapeutics' future performance. Based on our forecasts, it is anticipated that Aclaris will maintain a workforce of slightly above 90 employees by January 2025.Aclaris Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1939) % which means that it has lost $0.1939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2583) %, meaning that it created substantial loss on money invested by shareholders. Aclaris Therapeutics' management efficiency ratios could be used to measure how well Aclaris Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Aclaris Therapeutics Workforce Comparison
Aclaris Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 192,368. Aclaris Therapeutics adds roughly 86.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (1.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.23) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.23. Aclaris Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aclaris Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aclaris Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aclaris Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.7778 | 7 | 9 | 1,295,906 | 238,747 |
2024-09-01 | 1.7778 | 16 | 9 | 1,334,800 | 81,400 |
2024-06-01 | 2.3571 | 33 | 14 | 3,781,138 | 74,410 |
2024-03-01 | 1.0417 | 25 | 24 | 2,041,116 | 195,204 |
2023-09-01 | 0.7143 | 5 | 7 | 55,770 | 47,704 |
2023-06-01 | 2.25 | 27 | 12 | 216,085 | 58,805 |
2023-03-01 | 0.8065 | 25 | 31 | 1,300,354 | 442,292 |
2022-06-01 | 1.9231 | 25 | 13 | 215,897 | 143,766 |
2022-03-01 | 1.2 | 24 | 20 | 1,340,919 | 382,396 |
2021-12-01 | 0.5 | 1 | 2 | 8,276 | 1,960,404 |
2021-09-01 | 0.5 | 2 | 4 | 8,333 | 12,005 |
2021-06-01 | 0.5106 | 24 | 47 | 437,157 | 972,376 |
2021-03-01 | 0.84 | 21 | 25 | 968,241 | 320,514 |
2020-12-01 | 0.5 | 3 | 6 | 6,068 | 7,807 |
2020-09-01 | 0.75 | 3 | 4 | 172,184 | 114,324 |
2020-06-01 | 1.2857 | 18 | 14 | 402,888 | 334,894 |
2020-03-01 | 1.5217 | 35 | 23 | 1,446,268 | 354,961 |
2019-12-01 | 0.5833 | 7 | 12 | 186,316 | 14,341 |
2019-09-01 | 1.0 | 2 | 2 | 22,000 | 7,648 |
2019-06-01 | 0.4286 | 6 | 14 | 43,998 | 1,770,150 |
2019-03-01 | 1.1667 | 14 | 12 | 750,603 | 39,625 |
2018-12-01 | 0.875 | 21 | 24 | 398,954 | 25,346 |
2018-09-01 | 1.0 | 2 | 2 | 12,850 | 108,000 |
2018-06-01 | 0.9 | 18 | 20 | 136,716 | 217,838 |
2018-03-01 | 4.25 | 17 | 4 | 502,549 | 96,528 |
2017-12-01 | 0.5 | 10 | 20 | 16,991 | 22,156 |
2017-03-01 | 0.4 | 4 | 10 | 23,605 | 1,182,605 |
2016-12-01 | 0.8 | 16 | 20 | 497,569 | 1,654,108 |
2016-09-01 | 0.9091 | 10 | 11 | 424,717 | 1,235,282 |
2016-06-01 | 4.0 | 4 | 1 | 26,528 | 1,014,381 |
2015-12-01 | 0.8868 | 47 | 53 | 31,181,743 | 28,054,019 |
Aclaris Therapeutics Notable Stakeholders
An Aclaris Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aclaris Therapeutics often face trade-offs trying to please all of them. Aclaris Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aclaris Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Frank Ruffo | CFO CoFounder | Profile | |
Neal DO | President, CoFounder | Profile | |
Hugh Davis | President COO | Profile | |
Steven PharmD | Regulatory President | Profile | |
MD DO | President CoFounder | Profile | |
Joseph Monahan | Chief Officer | Profile | |
Gail MD | Chief Officer | Profile | |
Robert Doody | VP Relations | Profile | |
Matthew JD | General Secretary | Profile | |
MD Frcp | Pres COO | Profile | |
Kevin Balthaser | Chief Officer | Profile | |
MD MBA | Senior Development | Profile | |
Steve Tucker | Senior Leadership | Profile | |
Ian Anderson | Ex RD | Profile | |
Jon Jacobsen | Senior Chemistry | Profile | |
James Loerop | Chief Officer | Profile | |
Paul Changelian | VP Biology | Profile |
About Aclaris Therapeutics Management Performance
The success or failure of an entity such as Aclaris Therapeutics often depends on how effective the management is. Aclaris Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aclaris management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aclaris management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Please note, the imprecision that can be found in Aclaris Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aclaris Therapeutics. Check Aclaris Therapeutics' Beneish M Score to see the likelihood of Aclaris Therapeutics' management manipulating its earnings.
Aclaris Therapeutics Workforce Analysis
Traditionally, organizations such as Aclaris Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aclaris Therapeutics within its industry.Aclaris Therapeutics Manpower Efficiency
Return on Aclaris Therapeutics Manpower
Revenue Per Employee | 363.4K | |
Revenue Per Executive | 1.8M | |
Net Loss Per Employee | 1M | |
Net Loss Per Executive | 5.2M | |
Working Capital Per Employee | 1.1M | |
Working Capital Per Executive | 5.8M |
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.